Neprilysin Inhibition in the Time of Precision Medicine*

JACC: Heart Failure

Volumn 4, Issue 5, 2016, Pages 409-414

  Feldman, Arthur M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; Alzheimer's disease; Angiotensin converting enzyme inhibitor; Heart failure; Neprilysin

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN; BRAIN NATRIURETIC PEPTIDE; CAPTOPRIL; CREATININE; ENALAPRIL; ENKEPHALINASE INHIBITOR; LISINOPRIL; LOSARTAN; OMAPATRILAT; PLACEBO; SACUBITRIL PLUS VALSARTAN; VALSARTAN;

ALZHEIMER DISEASE; AMNESIA; ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEFIBRILLATION; DEMENTIA; DISEASE EXACERBATION; DRUG COST; DRUG MEGADOSE; DRUG RESEARCH; EDITORIAL; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE DP-DT; HEART OUTPUT; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; HYPOTENSION; LOW DRUG DOSE; MACACA FASCICULARIS; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; NONHUMAN; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 84963974176     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.02.016     Document Type: Editorial

References (51)

1. McMurray J.J., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014, 371:993-1004.
2. Packer M. Love of ACE inhibitors in the time of cholera. J Am Coll Cardiol HF 2016, 4:403-408.
3. Flores A. Magical realism in Spanish American fiction. Hispania 1955, 38:187-192.
4. Fitzpatrick M.A., Rademaker M.T., Charles C.J., et al. Acute hemodynamic, hormonal, and renal effects of neutral endopeptidase inhibition in ovine heart failure. J Cardiovasc Pharmacol 1992, 19:635-640.
5. Abassi Z.A., Yahia A., Zeid S., et al. Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure. Am J Physiol Heart Circ Physiol 2005, 288:H722-H728.
6. Maki T., Nasa Y., Tanonaka K., Takahashi M., Takeo S. Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure. Mol Cell Biochem 2003, 254:265-273.
7. von Lueder T.G., Wang B.H., Kompa A.R., et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail 2015, 8:71-78.
8. Trippodo N.C., Fox M., Monticello T.M., Panchal B.C., Asaad M.M. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 1999, 34:782-790.
9. Lapointe N., Blais C., Adam A., et al. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J Am Coll Cardiol 2002, 39:1692-1698.
10. Lapointe N., Tsoporis J.N., Parker T.G., et al. Comparative effects of a vasopeptidase inhibitor vs. an angiotensin converting enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure. Mol Cell Biochem 2003, 254:235-245.
11. Suematsu Y., Miura S.I., Goto M., et al. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Eur J Heart Fail 2016, Jan 7 [Epub ahead of print].
12. Kentsch M., Otter W., Drummer C., Notges A., Gerzer R., Muller-Esch G. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol 1996, 51:269-272.
13. Rouleau J.L., Pfeffer M.A., Stewart D.J., et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000, 356:615-620.
14. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62:e147-e239.
15. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999, 100:2312-2318.
16. Konstam M.A., Neaton J.D., Dickstein K., et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009, 374:1840-1848.
17. McNamara D.M., Holubkov R., Postava L., et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004, 44:2019-2026.
18. Nanas J.N., Alexopoulos G., Anastasiou-Nana M.I., et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group. J Am Coll Cardiol 2000, 36:2090-2095.
19. Tang W.H., Vagelos R.H., Yee Y.G., et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002, 39:70-78.
20. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429-1435.
21. Mair J., Lindahl B., Giannitsis E., et al. Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?. Eur Heart J Acute Cardiovasc Care 2016, Jan 12 [Epub ahead of print].
22. Feldman A.M., Haller J.A., DeKosky S.T. Valsartan/sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations. JAMA 2016, 315:25-26.
23. Nalivaeva N.N., Belyaev N.D., Kerridge C., Turner A.J. Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease. Front Aging Neurosci 2014, 6:235.
24. Iwata N., Higuchi M., Saido T.C. Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol Ther 2005, 108:129-148.
25. Iwata N., Tsubuki S., Takaki Y., et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000, 6:143-150.
26. Baranello R.J., Bharani K.L., Padmaraju V., et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr Alzheimer Res 2015, 12:32-46.
27. Krohn M., Bracke A., Avchalumov Y., et al. Accumulation of murine amyloid-beta mimics early Alzheimer's disease. Brain 2015, 138:2370-2382.
28. de Toledo Ferraz Alves T.C., Ferreira L.K., Wajngarten M., Busatto G.F. Cardiac disorders as risk factors for Alzheimer's disease. J Alzheimers Dis 2010, 20:749-763.
29. Jefferson A.L., Himali J.J., Au R., et al. Relation of left ventricular ejection fraction to cognitive aging (from the Framingham Heart Study). Am J Cardiol 2011, 108:1346-1351.
30. Jefferson A.L., Himali J.J., Beiser A.S., et al. Cardiac index is associated with brain aging: the Framingham Heart Study. Circulation 2010, 122:690-697.
31. Qiu C., Winblad B., Marengoni A., Klarin I., Fastbom J., Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med 2006, 166:1003-1008.
32. Li Y., Wang J., Zhang S., Liu Z. Neprilysin gene transfer: A promising therapeutic approach for Alzheimer's disease. J Neurosci Res 2015, 93:1325-1329.
33. Carpentier M., Robitaille Y., DesGroseillers L., Boileau G., Marcinkiewicz M. Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002, 61:849-856.
34. Yasojima K., McGeer E.G., McGeer P.L. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res 2001, 919:115-121.
35. Huang S.M., Mouri A., Kokubo H., et al. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 2006, 281:17941-17951.
36. Betts V., Leissring M.A., Dolios G., Wang R., Selkoe D.J., Walsh D.M. Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiol Dis 2008, 31:442-450.
37. Wood L.S., Pickering E.H., McHale D., Dechairo B.M. Association between neprilysin polymorphisms and sporadic Alzheimer's disease. Neurosci Lett 2007, 427:103-106.
38. Iwata N., Takaki Y., Fukami S., Tsubuki S., Saido T.C. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 2002, 70:493-500.
39. Ohno-Matsui K. Parallel findings in age-related macular degeneration and Alzheimer's disease. Prog Retin Eye Res 2011, 30:217-238.
40. Anderson D.H., Talaga K.C., Rivest A.J., Barron E., Hageman G.S., Johnson L.V. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 2004, 78:243-256.
41. He Y., Zhao H., Su G. Ginsenoside Rg1 decreases neurofibrillary tangles accumulation in retina by regulating activities of neprilysin and PKA in retinal cells of AD mice model. J Mol Neurosci 2014, 52:101-106.
42. Wang J., Ohno-Matsui K., Morita I. Elevated amyloid beta production in senescent retinal pigment epithelium, a possible mechanism of subretinal deposition of amyloid beta in age-related macular degeneration. Biochem Biophys Res Commun 2012, 423:73-78.
43. Parthasarathy R., Chow K.M., Derafshi Z., et al. Reduction of amyloid-beta levels in mouse eye tissues by intra-vitreally delivered neprilysin. Exp Eye Res 2015, 138:134-144.
44. Deane R., Zlokovic B.V. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2007, 4:191-197.
45. Ujiie M., Dickstein D.L., Carlow D.A., Jefferies W.A. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003, 10:463-470.
46. Erickson M.A., Banks W.A. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab 2013, 33:1500-1513.
47. Vodovar N., Paquet C., Mebazaa A., Launay J.M., Hugon J., Cohen-Solal A. Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?. Eur Heart J 2015, 36:902-905.
48. U.S. Food and Drug Administration. New Drug Application Approval Letter. 2015. Available at: . Accessed November 30, 2015. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207620Orig1s000ltr.pdf.
49. Ollendorf D.A., Sandhu A.T., Pearson S.D. Sacubitril-valsartan for the treatment of heart failure effectiveness and value. JAMA Internal Medicine 2016, 175:249-250.
50. Albert M.S., DeKosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
51. American Academy of Opthalmology. AAO Retina/Vitreous PPP Panel, Hoskins Center for Quality Eye Care. Age-Related Macular Degeneration PPP. 2015. Available at: . Accessed November 15, 2015. http://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015.